Anktiva is hard to find due to BCG shortages, specialty distribution, and insurance hurdles. Learn why access is limited and what you can do about it.
If you or a loved one has been prescribed Anktiva (nogapendekin alfa inbakicept-pmln) for bladder cancer, you may have already discovered that getting this medication isn't straightforward. You're not alone — many patients across the country are struggling to access this first-in-class immunotherapy.
In this guide, we'll break down the reasons why Anktiva is so hard to find in 2026 and give you practical steps to get the treatment you need.
Anktiva is a groundbreaking cancer immunotherapy approved by the FDA in April 2024. It's the first IL-15 superagonist ever approved for medical use. It works by supercharging your immune system — specifically your natural killer cells and T cells — to recognize and destroy bladder cancer cells.
Anktiva is approved for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). For many patients, it represents a chance to avoid having their bladder removed (a surgery called a cystectomy). In clinical trials, Anktiva plus BCG eliminated cancer in more than 62% of patients.
The catch? Anktiva must be used in combination with BCG — and that's where the problems begin.
The biggest barrier to accessing Anktiva treatment isn't actually Anktiva itself — it's BCG (Bacillus Calmette-Guérin). BCG is a standard treatment for early-stage bladder cancer and a required companion therapy for Anktiva.
Here's the problem: Merck remains the sole supplier of BCG (TICE BCG) in the United States, and there has been a severe shortage for years. This shortage worsened in 2025 and continues into 2026. Without BCG, doctors cannot administer Anktiva.
ImmunityBio, the company behind Anktiva, is developing a recombinant BCG (rBCG) to help address the shortage. They anticipated making over 45,000 vials available in 2025. However, the shortage remains a significant bottleneck for treatment access.
Unlike a typical prescription you'd pick up at your local pharmacy, Anktiva is a specialty medication. It's distributed only through specialty distributors like Cencora (formerly AmerisourceBergen). Your doctor's office or treatment center orders it directly — you can't walk into a CVS or Walgreens and fill this prescription.
This means access depends heavily on your healthcare provider's relationship with the specialty distributor and their ability to manage the buy-and-bill process.
Anktiva carries a wholesale acquisition cost (WAC) of about $35,800 per dose. A full course of treatment (induction plus maintenance over up to 37 months) can cost between $750,000 and $1 million or more.
While insurance coverage has been expanding since the permanent J-code (J9028) was issued in January 2025, getting coverage approved isn't automatic. Most insurers require:
Denials and delays are common, especially with newer medications. If your claim is denied, don't give up — appeal processes exist and the ImmunityBio CARE program can help.
Anktiva is prescribed almost exclusively by urologic oncologists and urologists who specialize in bladder cancer. Not every urology practice has experience with this medication or the infrastructure to administer intravesical treatments with it.
If you live in a rural area or a region without a major cancer center, finding a provider who can prescribe and administer Anktiva may require traveling. For help finding a specialist, check out our guide on how to find a doctor who can prescribe Anktiva near you.
Anktiva was only approved in April 2024, making it less than two years old on the market. New specialty oncology medications always face early access challenges:
The good news is that adoption is growing rapidly. ImmunityBio reported 700% year-over-year revenue growth for Anktiva in 2025, driven by repeat prescribing and growing physician confidence.
If you're having trouble accessing Anktiva, here are concrete steps you can take:
For more detailed tips, read our guide on how to find Anktiva in stock near you.
There are reasons to be optimistic about Anktiva access improving over time:
In the meantime, being proactive and using the resources available to you is the best way to overcome the current access barriers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
